Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Nektar Therapeutics (NASDAQ:NKTR)

15.20
Delayed Data
As of Jul 22
 -0.19 / -1.23%
Today’s Change
9.16
Today|||52-Week Range
17.55
-9.79%
Year-to-Date
Actelion (ALIOF) Beats Q2 Earnings & Revenues, View Up
Jul 22 / Zacks.com - Paid Partner Content
Aegerion to Withdraw Juxtapid from EU, Reduces Workforce
Jul 21 / Zacks.com - Paid Partner Content
Nutrisystem (NTRI) Q2 Earnings: What's in the Cards?
Jul 22 / Zacks.com - Paid Partner Content
Zafgen Halts Development of Beloranib, to Cut Jobs by ~34%
Jul 20 / Zacks.com - Paid Partner Content
C.R. Bard (BCR) Well Poised to Beat Q2 Earnings Estimates?
Jul 21 / Zacks.com - Paid Partner Content
Valeant/Progenics Relistor Ok'd; FDA Panel Backs Brodalumab
Jul 20 / Zacks.com - Paid Partner Content
Nektar Therapeutics (NKTR) Flagged As Strong On High Volume
Jul 21 / TheStreet.com - Paid Partner Content
Sarepta (SRPT) Posts Y/Y Wider Q2 Loss, Eteplirsen in Focus
Jul 20 / Zacks.com - Paid Partner Content
Express Scripts (ESRX) Q2 Earnings: Stock to Disappoint?
Jul 21 / Zacks.com - Paid Partner Content
Bristol-Myers' Opdivo Label Expansion Under U.S., EU Review
Jul 19 / Zacks.com - Paid Partner Content
Baxter International (BAX) Q2 Earnings: What's in Store?
Jul 21 / Zacks.com - Paid Partner Content
Merck KGaA's Multiple Sclerosis Drug under Review in EU
Jul 19 / Zacks.com - Paid Partner Content
Can CryoLife (CRY) Earnings Spring a Surprise in Q2?
Jul 21 / Zacks.com - Paid Partner Content
Evoke (EVOK) Stock Down on Poor Phase III EVK-001 Data
Jul 19 / Zacks.com - Paid Partner Content